Characterizing expanded access and compassionate use programs for experimental drugs

by Jennifer E. Miller, Joseph S. Ross, Kenneth I. Moch, Arthur L. Caplan
Published 2017-07-01

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis

by Joshua D. Wallach, Anita T. Luxkaranayagam, Sanket S. Dhruva, Jennifer E. Miller, Joseph S. Ross
Published 2019-06-01

Association of the FDA Amendment Act with trial registration, publication, and outcome reporting

by Adam T. Phillips, Nihar R. Desai, Harlan M. Krumholz, Constance X. Zou, Jennifer E. Miller, Joseph S. Ross
Published 2017-07-01

Adherence to the International Committee of Medical Journal Editors’ (ICMJE) prospective registration policy and implications for outcome integrity: a cross-sectional analysis of t...

by Anand D. Gopal, Joshua D. Wallach, Jenerius A. Aminawung, Gregg Gonsalves, Rafael Dal-Ré, Jennifer E. Miller, Joseph S. Ross
Published 2018-08-01

Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study

by Constance X. Zou, Jessica E. Becker, Adam T. Phillips, James M. Garritano, Harlan M. Krumholz, Jennifer E. Miller, Joseph S. Ross
Published 2018-10-01